Thousands of people in England at increased risk of oesophageal cancer could be offered an innovative seven-minute test on the NHS. The "sponge on a string" technique checks for Barrett’s oesophagus, a condition that occurs when stomach acid damages the lining of the food pipe. In some individuals, cells may grow abnormally and eventually develop into oesophageal cancer.
The National Institute for Health and Care Excellence (Nice) has recommended two tests – Cytosponge and EndoSign – for NHS deployment under new draft guidance. Tested during pilot schemes, the non-sedative technology can be administered in GP surgeries, local pharmacies and community diagnostic centres. The patient swallows a small capsule attached to a string, which dissolves inside the stomach to release a small sponge.
A Cytosponge test, one of those used to help diagnose oesophageal cancer. (PA Media) Pulled out using the string after a few minutes, the sponge collects cell samples from the oesophageal lining for analysis in a laboratory. The complete process takes approximately seven minutes. Nice said its committee found patients prefer the sponge on a string test to endoscopy, which involves a thin tube with a camera at the end being passed through the throat.
More than 9,000 people a year are diagnosed with oesophageal cancer in the UK. It is often diagnosed late, when it is harder to treat. According to Nice, Barrett’s oesophagus impacts around 1 to 2 per cent of adults, and is common among those who have long-term acid reflux.
Most people do not go on to develop cancer, but the tests also offer a way for them to monitor their condition. Professor Jonathan Benger, chief executive of Nice, said: “Oesophageal cancer is very difficult to treat when it is diagnosed at a later stage, so identifying people sooner is really important. “For people with persistent acid reflux and other risk factors, there is an increased chance of developing Barrett’s oesophagus, which can increase their risk of oesophageal cancer.
“Capsule sponge tests offer a quick and less invasive way to detect concerning changes associated with oesophageal cancer or Barrett’s oesophagus, helping to identify people who should go on to have further tests and treatment. “This new technology has the potential to make testing easier for patients, while helping the NHS focus valuable endoscopy capacity on those who need it most.” Professor Peter Johnson, national clinical director for cancer at NHS England, said: “The NHS is always looking for better ways to get to the bottom of people’s symptoms, and thousands have already benefited from this incredibly efficient test through pilots we have been running, so it’s fantastic it is now being considered for roll-out across the country. “Many people have acid reflux, and having an easier way to check for changes in the lining of the oesophagus can make a big difference for patients – reducing the need for more complicated endoscopy tests and helping the NHS free up resources to find cancers at an earlier stage.” The recommendation is the first to be issued by Nice under the National HealthTech Access Programme.
The initiative was designed to identify cutting-edge technology and devices and assess whether they should be used routinely on the health service. Thomas Slater, director of healthtech at Nice, said the recommendation “is an important milestone” and “a real example of what we want it to achieve for patients and the NHS”. “Capsule sponge tests show how innovative health technologies can improve people’s experience of care and help the NHS use its resources more effectively,” he added.
“This is just the beginning. We want the programme to support consistent adoption of high-impact technologies across the country, ensuring they deliver benefits for patients and value for taxpayers.”
Source: The Independent




